Achieve Life Sciences (ACHV) Cash from Restructuring (2010 - 2015)
Achieve Life Sciences' (ACHV) quarterly Cash from Restructuring came in at -$194000.0 in Q1 2015, down 2.65% YoY from -$199271.7 in Q1 2014, and up 27.34% on a QoQ basis from -$267000.0 in Q4 2014.
Achieve Life Sciences (ACHV) Cash from Restructuring (2010 - 2015) Analysis & Trends
Achieve Life Sciences (ACHV) has 5 years of Cash from Restructuring data on file, last reported at -$194000.0 in Q1 2015.
- Quarterly Cash from Restructuring fell 2.65% year-over-year to -$194000.0 in Q1 2015, while the trailing twelve-month figure through Dec 2015 was -$194000.0 (up 77.15% YoY) and the FY2015 annual result came in at -$194000.0, up 75.29% from the prior year.
- Cash from Restructuring improved to -$194000.0 in Q1 2015, from -$267000.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of -$164000.0 in Q1 2013 to a low of -$1.7 million in Q4 2012.
- A 4-year average of -$338000.0 and a median of -$191500.0 in 2014 frame the typical range for Cash from Restructuring.
- Annual changes were most pronounced in 2013 — Cash from Restructuring surged 89.38% — and 2014, when it slumped 51.7%.
- Tracing ACHV's Cash from Restructuring over 4 years: stood at -$1.7 million in 2012, then surged by 89.38% to -$176000.0 in 2013, then tumbled by 51.7% to -$267000.0 in 2014, then increased by 27.34% to -$194000.0 in 2015.
- The last three Cash from Restructuring figures came in at -$194000.0 (Q1 2015), -$267000.0 (Q4 2014), and -$199000.0 (Q3 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | -194,000.00 |
| Dec 31, 2014 | -267,000.00 |
| Sep 30, 2014 | -199,000.00 |
| Jun 30, 2014 | -194,000.00 |
| Mar 31, 2014 | -189,000.00 |
| Dec 31, 2013 | -176,000.00 |
| Sep 30, 2013 | -173,000.00 |
| Jun 30, 2013 | -167,000.00 |
| Mar 31, 2013 | -164,000.00 |
| Dec 31, 2012 | -1.66 Mn |
| Sep 30, 2010 | 4.04 Mn |